Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06324357

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Led by Boehringer Ingelheim · Updated on 2026-04-29

768

Participants Needed

108

Research Sites

240 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

CONDITIONS

Official Title

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients 18 years of age or older or over the legal age of consent
  • Documented HER2-positive metastatic breast cancer or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma for cohorts A to K and O
  • Documented HER2-positive metastatic colorectal cancer for cohorts L, M, and N
  • Provision of tumor tissue from non-radiated sites for Phase II dose optimization if possible
  • History of prior treatment with documented progression after HER2-directed therapy for specified cohorts
  • At least one measurable lesion according to RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function based on laboratory tests
Not Eligible

You will not qualify if you...

  • Previous treatment with small molecule HER2 inhibitors in specified cohorts (D, E, F, H, L, M, N), with some exceptions
  • Previous treatment with trastuzumab deruxtecan in cohorts E and F, with some exceptions
  • Previous treatment with trastuzumab emtansine in cohorts D and H, with some exceptions
  • Previous treatment with capecitabine in cohorts D and H, with some exceptions
  • Uncontrolled or symptomatic brain metastases or leptomeningeal disease
  • Corrected QT interval (QTcF) greater than 470 msec
  • Conditions increasing risk of QT prolongation or arrhythmia, such as heart failure or congenital long QT syndrome
  • Ejection fraction below 50% or institutional lower limit of normal within 28 days prior to randomization
  • History or current interstitial lung disease or pneumonitis requiring steroids, or suspected cases not ruled out by imaging at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 108 locations

1

Mayo Clinic-Arizona

Phoenix, Arizona, United States, 85054

Not Yet Recruiting

2

The Oncology Institute of Hope and Innovation

Cerritos, California, United States, 90703

Not Yet Recruiting

3

Ellison Medical Institute

Los Angeles, California, United States, 90064

Not Yet Recruiting

4

Valkyrie Clinical Trials

Los Angeles, California, United States, 90067

Actively Recruiting

5

University of California Los Angeles

Los Angeles, California, United States, 90095

Not Yet Recruiting

6

University of California Irvine

Orange, California, United States, 92868

Actively Recruiting

7

Sharp Memorial Hospital

San Diego, California, United States, 92123

Not Yet Recruiting

8

Yale University School of Medicine

New Haven, Connecticut, United States, 06510

Actively Recruiting

9

Mayo Clinic - Florida

Jacksonville, Florida, United States, 32224

Not Yet Recruiting

10

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States, 33612

Not Yet Recruiting

11

Orchard Healthcare Research Inc.- Skokie

Skokie, Illinois, United States, 60077

Not Yet Recruiting

12

Community Health Network

Indianapolis, Indiana, United States, 46250

Not Yet Recruiting

13

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242

Actively Recruiting

14

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

15

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Not Yet Recruiting

16

University of Michigan

Ann Arbor, Michigan, United States, 48109

Not Yet Recruiting

17

Mayo Clinic, Rochester

Rochester, Minnesota, United States, 55905

Not Yet Recruiting

18

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10065

Not Yet Recruiting

19

New York Cancer & Blood Specialists

Shirley, New York, United States, 11967

Not Yet Recruiting

20

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Not Yet Recruiting

21

Avera Cancer Institute

Sioux Falls, South Dakota, United States, 57105

Not Yet Recruiting

22

Baptist Cancer Center - Memphis

Memphis, Tennessee, United States, 38120

Not Yet Recruiting

23

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

24

Tennessee Oncology, Pllc

Nashville, Tennessee, United States, 37203

Actively Recruiting

25

The Methodist Hospital Research Institute

Houston, Texas, United States, 77030

Not Yet Recruiting

26

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Not Yet Recruiting

27

Inova Schar Cancer Institute

Fairfax, Virginia, United States, 22031

Not Yet Recruiting

28

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States, 22031

Actively Recruiting

29

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States, 98109

Actively Recruiting

30

Cliniques Universitaires Saint-Luc

Brussels, Belgium, 1200

Not Yet Recruiting

31

Edegem - UNIV UZ Antwerpen

Edegem, Belgium, 2650

Actively Recruiting

32

UZ Leuven

Leuven, Belgium, 3000

Actively Recruiting

33

Hôpital Vivalia De Libramont

Libramont-Chevigny, Belgium, 6800

Actively Recruiting

34

Centre Hospitalier Universitaire de Liège

Liège, Belgium, 4000

Terminated

35

CHU UCL Namur

Namur, Belgium, 5000

Actively Recruiting

36

Jilin Province Cancer Hospital

Changchun, China, 130012

Actively Recruiting

37

The First Hospital of Jilin University

Changchun, China, 130021

Not Yet Recruiting

38

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, China, 310000

Actively Recruiting

39

Harbin Medical University Cancer Hospital

Harbin, China, 150081

Actively Recruiting

40

Jiangsu Province Hospital

Nanjing, China, 210029

Actively Recruiting

41

Fudan University Shanghai Cancer Center

Shanghai, China, 200032

Actively Recruiting

42

Tianjin Cancer Hospital

Tianjin, China, 300060

Actively Recruiting

43

Henan Cancer Hospital

Zhengzhou, China, 450003

Actively Recruiting

44

INS Bergonie

Bordeaux, France, 33000

Not Yet Recruiting

45

CTR François Baclesse

Caen, France, 14076

Not Yet Recruiting

46

CTR Georges-François Leclerc

Dijon, France, 21000

Not Yet Recruiting

47

CTR Leon Berard

Lyon, France, 69008

Not Yet Recruiting

48

INS Paoli-Calmettes

Marseille, France, 13273

Not Yet Recruiting

49

HOP Tenon

Paris, France, 75020

Not Yet Recruiting

50

CTR Eugène Marquis

Rennes, France, 35042

Not Yet Recruiting

51

Institut de Cancérologie de l'Ouest

Saint-Herblain, France, 44800

Not Yet Recruiting

52

Institut de Cancérologie de Strasbourg

Strasbourg, France, 67200

Not Yet Recruiting

53

INS Claudius Regaud IUCT-Oncopole

Toulouse, France, 31059

Not Yet Recruiting

54

Institut Gustave Roussy

Villejuif, France, 94805

Not Yet Recruiting

55

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, Germany, 01307

Not Yet Recruiting

56

Universitätsklinikum Erlangen

Erlangen, Germany, 91054

Not Yet Recruiting

57

Evang. Kliniken Essen-Mitte gGmbh

Essen, Germany, 45136

Not Yet Recruiting

58

Asklepios Kliniken GmbH & Co. KGaA

Hamburg, Germany, 22763

Not Yet Recruiting

59

Universitätsklinikum Mannheim GmbH

Mannheim, Germany, 68167

Not Yet Recruiting

60

Universitätsklinikum Ulm

Ulm, Germany, 89075

Not Yet Recruiting

61

Istituto Di Candiolo

Candiolo (TO), Italy, 10060

Not Yet Recruiting

62

Az.Osp. Universitaria "Ospedali Riuniti"

Foggia, Italy, 71122

Not Yet Recruiting

63

Istituto Scientifico Romagnolo

Meldola (FC), Italy, 47014

Not Yet Recruiting

64

Ospedale San Raffaele S.r.l.

Milan, Italy, 20132

Actively Recruiting

65

Istituto Europeo di Oncologia

Milan, Italy, 20141

Actively Recruiting

66

Humanitas Istituto Clinico Catanese S.p.A.

Misterbianco (CT), Italy, 95045

Not Yet Recruiting

67

Istituto Nazionale IRCCS Tumori Fondazione Pascale

Naples, Italy, 80131

Not Yet Recruiting

68

Istituto Clinico Humanitas

Rozzano, Italy, 20089

Actively Recruiting

69

Aichi Cancer Center Hospital

Aichi, Nagoya, Japan, 464-8681

Not Yet Recruiting

70

Tokai University Hospital

Isehara, Japan, 259-1193

Not Yet Recruiting

71

Hakuaikai Sagara Hospital

Kagoshima, Japan, 892-0833

Actively Recruiting

72

Kanagawa Cancer Center

Kanagawa, Yokohama, Japan, 241-8515

Actively Recruiting

73

National Cancer Center Hospital East

Kashiwa-shi, Japan, 277-8577

Actively Recruiting

74

Kyoto University Hospital

Kyoto, Japan, 606-8507

Actively Recruiting

75

Osaka International Cancer Institute

Osaka, Japan, 541-8567

Actively Recruiting

76

Japanese Foundation for Cancer Research

Tokyo, Koto-ku, Japan, 135-8550

Actively Recruiting

77

CHA Bundang Medical Center

Seongnam-si, South Korea, 13496

Actively Recruiting

78

Seoul National University Bundang Hospital

Seongnam-si, South Korea, 13620

Actively Recruiting

79

Severance Hospital, Yonsei University Health System

Seoul, South Korea, 03722

Actively Recruiting

80

Asan Medical Center

Seoul, South Korea, 05505

Actively Recruiting

81

Korea University Anam Hospital

Seoul, South Korea, 2841

Actively Recruiting

82

Seoul National University Hospital

Seoul, South Korea, 3080

Not Yet Recruiting

83

The Catholic University of Korea, Seoul St.Mary's Hospital

Seoul, South Korea, 6273

Not Yet Recruiting

84

Severance Hospital, Yonsei University Health System

Seoul, South Korea, 6591

Actively Recruiting

85

Hospital Teresa Herrera

A Coruña, Spain, 15006

Actively Recruiting

86

Hospital del Mar

Barcelona, Spain, 08003

Actively Recruiting

87

Hospital Universitari Vall d'Hebron

Barcelona, Spain, 08035

Actively Recruiting

88

Hospital Clínic de Barcelona

Barcelona, Spain, 08036

Actively Recruiting

89

Hospital Duran i Reynals

L'Hospitalet de Llobregat, Spain, 8906

Actively Recruiting

90

Hospital General Universitario Gregorio Marañón

Madrid, Spain, 28007

Not Yet Recruiting

91

Clínica Universidad de Navarra - Madrid

Madrid, Spain, 28022

Actively Recruiting

92

Fundación Jiménez Díaz

Madrid, Spain, 28040

Actively Recruiting

93

Hospital Clínico San Carlos

Madrid, Spain, 28040

Not Yet Recruiting

94

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

95

Hospital Universitario La Paz

Madrid, Spain, 28046

Actively Recruiting

96

CIO Clara Campal

Madrid, Spain, 28050

Actively Recruiting

97

Hospital Universitario Virgen De La Macarena

Seville, Spain, 41009

Actively Recruiting

98

Instituto Valenciano de Oncología

Valencia, Spain, 46009

Not Yet Recruiting

99

Velindre Cancer Centre

Cardiff, United Kingdom, CF14 2TL

Not Yet Recruiting

100

St James's University Hospital

Leeds, United Kingdom, LS9 7TF

Not Yet Recruiting

101

St Bartholomew's Hospital

London, United Kingdom, EC1A 7BE

Not Yet Recruiting

102

University College Hospital

London, United Kingdom, NW1 2BU

Actively Recruiting

103

Royal Free Hospital

London, United Kingdom, NW3 2QG

Actively Recruiting

104

The Royal Marsden Hospital, London

London, United Kingdom, SW3 6JJ

Not Yet Recruiting

105

The Christie Hospital

Manchester, United Kingdom, M20 4BX

Actively Recruiting

106

Freeman Hospital

Newcastle upon Tyne, United Kingdom, NE7 7DN

Not Yet Recruiting

107

Nottingham University Hospital

Nottingham, United Kingdom, NG5 1PB

Not Yet Recruiting

108

The Royal Marsden Hospital, Sutton

Sutton, United Kingdom, SM2 5PT

Not Yet Recruiting

Loading map...

Research Team

B

Boehringer Ingelheim

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

18

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here